ライフサイエンスコーパス: iron supplementation

1 chondrial function, which can be reversed by iron supplementation.

2 on the change in iron status in response to iron supplementation.

3 sed as a safe and easily available source of iron supplementation.

4 All patients received iron supplementation.

5 nt iron uptake, since it can be corrected by iron supplementation.

6 but who suffer from fatigue may benefit from iron supplementation.

7 evere growth defect, which can be rescued by iron supplementation.

8 results, and have not accounted for maternal iron supplementation.

9 hemoglobin concentrations were improved with iron supplementation.

10 e risk factors under different conditions of iron supplementation.

11 Otherwise, predictors varied by iron supplementation.

12 a severe growth defect corrected by in vivo iron supplementation.

13 This impairment can be corrected with iron supplementation.

14 absorption had decreased significantly with iron supplementation.

15 ed women and that this can be corrected with iron supplementation.

16 eme-iron absorption from food in response to iron supplementation.

17 rapy is an accepted and convenient method of iron supplementation.

18 and should be complemented with school-based iron supplementation.

19 lacental transfer and impair the efficacy of iron supplementation.

20 an lead to anemia despite erythropoietin and iron supplementation.

21 on, especially for antenatal care, including iron supplementation.

22 s by region and worsens in pregnancy without iron supplementation.

23 and, as such, are routinely recommended for iron supplementation.

24 factors when formulating recommendations on iron supplementation.

25 prevention, including food fortification and iron supplementation.

26 a loss of appetite that can be restored with iron supplementation.

27 dly elevated growth in serum collected after iron supplementation.

28 tions that result from long-term intravenous iron supplementation.

29 intervention groups.LBW children who receive iron supplementation (1 or 2 mg Fe . d(-1)) in infancy h

30 9 days (n = 112) and 84 days (n = 115) after iron supplementation (60 mg iron as ferrous fumarate dai

31 ay) rats and in both groups after daily high-iron supplementation (8,000 microg/day) for 34 days.

32 nemia); A, ID, T (no anemia, iron-deficient, iron supplementation); A (anemia); and A, ID, T (anemia,

33 In contrast, in cells grown with iron supplementation, a PerR-repressed gene is completel

34 ract agar with a reduced amount of its usual iron supplementation, a phenotype that could be compleme

35 Consistent with this, iron supplementation accelerates symptoms of brain degen

36 emia); and A, ID, T (anemia, iron-deficient, iron supplementation) according to hemoglobin level, iro

37 Exclusion criteria were already taking iron supplementation, acute illness, current opportunist

38 f these studies was to determine how dietary iron supplementation affected the severity of allergic i

39 Iron supplementation after cecal ligation and puncture i

40 Iron supplementation after sham laparotomy did not cause

41 d systemic bacterial counts in animals given iron supplementation after the onset of sepsis.

42 Question: What are the benefits and harms of iron supplementation alone and as an adjunct to erythrop

43 We determined whether n-3 LCPUFAs and iron supplementation, alone or in combination, affected

44 The patients who received iron supplementation also had a more rapid return of iro

45 Prenatal iron supplementation among iron-replete, nonanemic women

46 can be used to predict effects of trials of iron supplementation and fortification and to design iro

47 alth problem despite decades of efforts with iron supplementation and fortification.

48 ected by PS can support early individualized iron supplementation and neurodevelopmental follow-up to

49 ematologic response to supervised, long-term iron supplementation and the relation of this response t

50 valuating the effect on clinical outcomes of iron supplementation and therapies for alternative targe

51 tnatal management recommendations, including iron supplementation and thromboembolism prevention, wer

52 n labile iron pools within living cells with iron supplementation and/or depletion.

53 ew of randomized controlled trials (RCTs) of iron-supplementation and -fortification trials that asse

54 e., complex carbohydrate or ketogenic diet), iron supplementation, and albumin infusions.

55 he risk of GDM associated with dietary iron, iron supplementation, and iron status as measured by blo

56 diets, caloric supplementation, calcium and iron supplementation, and various other vitamin and mine

57 tion may lead to the development of improved iron supplementation approaches.

58 aining micronutrient powders (MNPs) and oral iron supplementation are both effective strategies to in

59 New indications of intravenous iron supplementation are emerging.

60 The benefits of iron supplementation are likely to outweigh possible ris

61 Current programs of universal iron supplementation are unlikely to have much effect on

62 reated iron deficiency, as well as excessive-iron supplementation, are deleterious and emphasize the

63 meostasis with the response to and risk from iron supplementation as well as the need for indicators

64 otential risks of a more liberal approach to iron supplementation as well as the potential risks and

65 t negative side effects related to high-dose iron supplementation as well as the significant proporti

66 Iron supplementation attenuated the decrement in iron st

67 Iron status is affected by BCT, and iron supplementation attenuates the decrement in indicat

68 rld Health Organization recommendations that iron supplementation be given in combination with malari

69 No benefit was found with daily low-dose iron supplementation between 4 and 9 months with respect

70 All patients should have iron supplementation both to correct anemia and replenis

71 During iron supplementation, both groups had high iron absorpti

72 al damage and cell death can be prevented by iron supplementation, but cannot be fully blocked by a p

73 idin can determine individuals' responses to iron supplementation, but limited evidence exists from p

74 Adverse effects of intravenous iron supplementation by ferric carboxymaltose seem to be

75 Taken together, these studies show that iron supplementation can decrease the severity of allerg

76 mon nutritional deficiency in the world, but iron supplementation can increase risk of opportunistic

77 tions are warranted to assess to what extent iron supplementation can prevent FGF23-mediated hypophos

78 Nevertheless, iron supplementation can prevent ventricular remodelling

79 lysis of this randomized trial confirms that iron supplementation can reverse elevated FGF23 producti

80 Iron supplementation caused modest augmentation of iron

81 Intravenous iron supplementation compared with placebo resulted in i

82 ngleton pregnancies, administration of daily iron supplementation, compared with administration of pl

83 deficient rats and rats receiving daily high-iron supplementation, compared with iron-normal rats (P

84 nors with normal hemoglobin levels, low-dose iron supplementation, compared with no supplementation,

85 We wanted to determine whether iron supplementation could prevent decrements in iron st

86 In vitro, iron supplementation decreased mast cell granule content

87 on depletion of culture medium enhanced, and iron supplementation decreased, the efficiency of infect

88 Maternal iron supplementation did not affect infant iron status a

89 In most of the studies, iron supplementation did not affect the biochemical stat

90 ence of iron deficiency is low, intermittent iron supplementation did not have any or negative effect

91 -deleted livers were iron deficient, dietary iron supplementation did not prevent steatosis; instead,

92 Intermittent iron supplementation did not result in any significant i

93 ive risk [RR], 1.03; 95% CI, 0.65-1.65), and iron supplementation did not significantly affect birth

94 Iron supplementation directly restores PHD catalytic act

95 s a sign of adequate iron nutrition, because iron supplementation does not increase hemoglobin higher

96 Iron supplementation dominated MNPs because it was cheap

97 children in each group who received 28 d of iron supplementation during antimalarial treatment with

98 status, indicators of iron sufficiency, and iron supplementation during inflammation and how it may

99 The increasing prevalence of indiscriminate iron supplementation during pregnancy also raises concer

100 ed meat consumption, the effects of too much iron supplementation during pregnancy have become a conc

101 There is limited evidence on the safety of iron supplementation during pregnancy in these areas.

102 The effect of iron supplementation during pregnancy may depend on init

103 In one randomized trial, iron supplementation during pregnancy reduced child mort

104 vidence supports the advisability of routine iron supplementation during pregnancy.

105 questions about the safety of indiscriminate iron supplementation during pregnancy.

106 stfed infants and tested the hypothesis that iron supplementation enhances iron status.

107 +MMN, and placebo groups, respectively.Daily iron supplementation for 12 wk increased hemoglobin in n

108 All children received iron supplementation for 6 weeks; children in the interv

109 We hypothesized that iron supplementation for 6 wk would significantly improv

110 ve malaria control can mitigate the risks of iron supplementation for children in areas of malaria tr

111 tes of the ESX-3 T7SS, esxG or esxH, require iron supplementation for in vitro growth and are highly

112 Furthermore, iron supplementation for iron deficient children in mala

113 d insufficient evidence to recommend routine iron supplementation for pregnant women or routine scree

114 the balance of benefits and harms of routine iron supplementation for pregnant women to prevent adver

115 WHO recommends daily iron supplementation for pregnant women, but adherence i

116 da and the United States recommend universal iron supplementation for pregnant women.

117 10, primary outcome) were 3.9 +/- 1.8 in the iron supplementation group and 4.0 +/- 2.2 in the placeb

118 7.2) with significantly higher values in the iron supplementation group.

119 Iron supplementation had an ICER of $1645 ($1333, $2153)

120 On the basis of 11 trials, routine maternal iron supplementation had inconsistent effects on rates o

121 Prenatal iron supplementation had no effects on infant iron statu

122 ive iron supplementation, those who received iron supplementation had shortened time to 80% hemoglobi

123 ormone concentrations, patients who received iron supplementation had significantly higher circulatin

124 Iron supplementation has been associated with greater su

125 Conversely, iron supplementation has been shown to be beneficial in

126 The practice of intravenous iron supplementation has grown as nephrologists have gra

127 Iron supplementation has modest efficacy, causes gastroi

128 ctional iron deficiency, but its response to iron supplementation has not been investigated in margin

129 nantly due to iron deficiency, but antenatal iron supplementation has uncertain health benefits and c

130 ll as alternative therapies, including diet, iron supplementation, herbal medications, and neurofeedb

131 o control IDA include daily and intermittent iron supplementation, home fortification with micronutri

132 otransfusion, duration of hospital stay, and iron supplementation; however, differences between the g

133 As previously reported, iron supplementation improved iron status in mothers and

134 n children with poor iron and n-3 FA status, iron supplementation improved verbal and nonverbal learn

135 non-anaemic iron-deficient adolescent girls, iron supplementation improved verbal learning and memory

136 We investigated whether intravenous iron supplementation improves fatigue and general health

137 Among women, iron supplementation improves physical and cognitive per

138 e on hematologic responses and malaria after iron supplementation in anemic (hemoglobin: 70-109 g/L)

139 Iron supplementation in anemic HIV-infected children has

140 Although the benefits of iron supplementation in anemic women are well recognized

141 The long-term benefits of antenatal iron supplementation in child survival are not known.

142 and neonatal benefits and harms of universal iron supplementation in developed countries as evidenced

143 bal health applications such as guiding safe iron supplementation in developing countries with high i

144 The value of prophylactic iron supplementation in elderly blood donors was evaluat

145 ficacy of inexpensive readily available oral iron supplementation in heart failure is unknown.

146 multicenter trials exploring the use of oral iron supplementation in heart failure, a therapy that is

147 Thus, iron supplementation in HIV-infected children living in

148 It is unknown whether iron supplementation in human immunodeficiency virus (HI

149 ifies the assessment of the effectiveness of iron supplementation in improving conventional iron stat

150 aining reduces the apparent effectiveness of iron supplementation in improving sFer and calls into qu

151 Multivariate logistic regression showed that iron supplementation in infancy reduced the odds of havi

152 he mean SBP in LBW children who had received iron supplementation in infancy was 2.2 mm Hg (95% CI: 0

153 ing about weighing the benefits and risks of iron supplementation in iron-deficient, iron-sufficient,

154 termine whether there are adverse effects of iron supplementation in iron-replete women.

155 Calculations of body iron in trials of iron supplementation in Jamaica and iron fortification i

156 re protective against severe malaria, whilst iron supplementation in malaria endemic regions is with

157 have raised concerns regarding the safety of iron supplementation in malaria-endemic regions.

158 Although iron supplementation in malaria-free areas mostly reduce

159 tential risks and benefits of IV versus oral iron supplementation in patients with CKD.

160 These results do not support use of oral iron supplementation in patients with HFrEF.

161 ITDI represents a more efficacious method of iron supplementation in PD patients receiving rhEPO.

162 Iron supplementation in preventive programs may need to

163 The safety of routine iron supplementation in settings where infectious diseas

164 eliminate the inhibition of growth caused by iron supplementation in the absence of Mn2+.

165 the superiority of parenteral iron over oral iron supplementation in the treatment of chemotherapy-in

166 the hemoglobin S phenotype of the effects of iron supplementation in the treatment of mild anemia.

167 omized controlled trials of preventive, oral iron supplementation in young children (aged 0-59 mo) li

168 f Feroglobin capsule compared with different iron supplementations in adult subjects diagnosed with n

169 Harms of iron supplementation included transient gastrointestinal

170 Iron supplementation increased ferritin from 11 +/- 14 m

171 Iron supplementation increased hepatic iron and serum he

172 82 days of iron supplementation increased mean haemoglobin concentr

173 Iron supplementation increased morbidity (mostly respira

174 Moreover, iron supplementation increased surface expression of the

175 Iron supplementation increased the activities of several

176 Thus iron supplementation increased the aerobic growth rate,

177 Iron supplementation increased the number of days with i

178 Iron supplementation increased the serum ferritin concen

179 While iron supplementation increases maternal iron status and

180 In cultured macrophages, iron supplementation induced reactive oxygen species and

181 Iron supplementation, iron fortification of foods target

182 ciency is a common cause of maternal anemia, iron supplementation is a common practice to reduce the

183 Dietary iron supplementation is associated with increased appeti

184 ked to adverse pregnancy outcomes, universal iron supplementation is common practice before and durin

185 Where both conditions are prevalent, iron supplementation is complicated by observations that

186 ficiency and chronic inflammation, therefore iron supplementation is frequently needed.

187 women with depleted iron reserves, prenatal iron supplementation is important for meeting iron requi

188 on is essential for a healthy pregnancy, and iron supplementation is nearly universally recommended,

189 e, but the risk of infection associated with iron supplementation is not well defined.

190 Oral iron supplementation is often associated with rapid onse

191 ntries, incomplete resolution of anemia with iron supplementation is often attributed to poor complia

192 Iron supplementation is recommended in populations in wh

193 g cause of anemia in sub-Saharan Africa, and iron supplementation is the standard of care during preg

194 C-reactive protein level and with oral or IV iron supplementation; it also reduced serum hepcidin lev

195 d-release preparations and intermittent oral iron supplementation lead to better overall compliance a

196 Iron supplementation led to increased birth weight.

197 Additional screening and iron supplementation may be warranted in this high-risk

198 ed by physiologic iron status, and therefore iron supplementation may have adverse effects even among

199 Consequently, while iron supplementation may improve pregnancy outcome when

200 Iron supplementation may increase malaria morbidity and

201 Previous evidence has shown that iron supplementation may increase malaria risk.

202 Furthermore, iron supplementation may prove to be beneficial for mood

203 These results suggest that maintenance iron supplementation may result in fewer infections than

204 ., transferrin receptor 1 and ferritin), and iron supplementation mitigated their cytotoxicity.

205 Iron supplementation must be prescribed to avoid chronic

206 Iron supplementation (n = 104) compared to placebo (n =

207 Maternal hemoglobin (n = 1255), iron supplementation (n = 7484), food-based iron intake

208 Iron supplementation of anemic females trended toward in

209 Associations of anemia and iron supplementation of anemic patients with median over

210 Based on these data, routine IV iron supplementation of anemic, critically ill trauma pa

211 The study assessed the effect of early iron supplementation of breastfed infants and tested the

212 Early iron supplementation of breastfed infants is feasible an

213 merozoite preference for young erythrocytes, iron supplementation of iron-deficient individuals rever

214 e suggesting adverse effects associated with iron supplementation of iron-replete individuals.

215 s, and 4) the balance of benefit and harm of iron supplementation of iron-replete pregnant women and

216 However, iron supplementation of iron-sufficient individuals is l

217 rkshop related to iron screening and routine iron supplementation of largely iron-replete pregnant wo

218 Iron supplementation of the diet resulted in lower level

219 vary with the life stage and especially with iron supplementation of the diet.

220 Iron supplementation of the medium promoted translation

221 the absence of iron and grew poorly without iron supplementation of the medium, phenotypes consisten

222 Iron supplementation of these iron-depleted, nonanemic w

223 We investigated the effects of iron supplementation on adaptation to aerobic training a

224 We also reviewed effects of iron supplementation on birth outcomes among women at lo

225 olled clinical trial assessed the effects of iron supplementation on cognitive function in adolescent

226 On day 10, no significant effect of iron supplementation on DMT1 and FPN1 gene expression or

227 rial was conducted to examine the effects of iron supplementation on hemoglobin, HIV disease progress

228 is study was to assess the effect of dietary iron supplementation on insulin resistance and the role

229 Effects of prenatal iron supplementation on maternal postpartum iron status

230 or cognition in children, yet the effects of iron supplementation on neurocognition remain unclear.

231 d, as are those that evaluate the effects of iron supplementation on neurocognitive outcomes.

232 to be learned about the benefits of maternal iron supplementation on the health and iron status of th

233 Variable effects of iron supplementation on the susceptibility to mycobacter

234 pression of DMT1 and FPN1 and the effects of iron supplementation on their expression and on iron abs

235 he underlying disease and not related to the iron supplementation only.

236 xchangeable iron stores in living cells upon iron supplementation or depletion, including labile iron

237 e CIA scaffold complex are strengthened upon iron supplementation or low oxygen tension, while iron c

238 randomly assigned at age 6 mo to high or low iron supplementation or no added iron.

239 mpact of the current North American prenatal iron supplementation policy, this review highlights the

240 nce of anemia to the ongoing pharmacological iron supplementation program.

241 s also unknown, but it could be relevant for iron supplementation programs aimed at combating anemia.

242 Iron supplementation programs have been successful in re

243 cost point-of-care hepcidin assays would aid iron supplementation programs in the developing world.

244 y affects mother-child interactions and that iron supplementation protects against these negative eff

245 A therapeutic approach to iron supplementation, rather than a public health-based

246 In a mouse-mosquito acquisition model, iron supplementation reduced dengue virus prevalence and

247 Antenatal iron supplementation reduced geometric mean total-FGF23

248 of BCG-infected mice revealed that moderate iron supplementation reduced inflammation, as measured b

249 cental malaria was not increased by maternal iron supplementation (relative risk [RR], 1.03; 95% CI,

250 Although intravenous iron supplementation remains the most effective therapy

251 ate aerobic exercise on the effectiveness of iron supplementation remains unclear.This study aimed to

252 uld not grow in tissue culture media without iron supplementation replicated more rapidly within epit

253 eatment with a peptide, Rho activator II, or iron supplementation rescued the molecular disease pathw

254 nactivation of the NUPR1-lipocalin-2 axis or iron supplementation rescues stemness and promotes the t

255 Remarkably, iron supplementation restores cell proliferation under b

256 Cysteine depletion or iron supplementation restores mitochondrial health in va

257 Iron supplementation resulted in improved (P < 0.05) vig

258 cellular level of mitochondrial aconitase by iron supplementation resulted in increased RNA-binding a

259 Iron supplementation reversed this growth defect and was

260 our findings imply that in malarious regions iron supplementation should be accompanied by effective

261 Iron supplementation should be administered intravenousl

262 Iron supplementation significantly decreased P(FIT2)-GFP

263 Iron supplementation significantly decreased the risk of

264 Random-effects meta-analyses showed that iron supplementation significantly improved iron status

265 Six weeks of iron supplementation significantly improved serum ferrit

266 Compared with placebo, iron supplementation significantly improved the mean inc

267 We previously showed that iron supplementation significantly improves iron status

268 Iron supplementation significantly reduced the risk of m

269 Iron supplementation starting at an early age may preven

270 Iron supplementation strategies in the developing world

271 eans, is a novel and natural alternative for iron supplementation strategies where effectiveness is l

272 igh risk of anemia, consensus was lacking on iron supplementation strategies.

273 Optimal oral iron supplementation strategy is unclear in patients wit

274 Data from pregnant women enrolled in the Iron Supplementation Study (Raleigh, North Carolina, 199

275 iency or iron deficiency anemia according to iron supplementation suggest that direct comparisons acr

276 was slightly but significantly higher after iron supplementation than after placebo (difference = 13

277 l adaptation, iron stores were greater after iron supplementation than after placebo and this differe

278 later in life.We investigated the effect of iron supplementation that was given to LBW infants on mi

279 uring the past year covers three main areas: iron supplementation, the regulation of iron absorption,

280 Additionally, current iron supplementation therapies benefit only certain pati

281 mpared with participants who did not receive iron supplementation, those who received iron supplement

282 dy, we used a rat model of long term dietary iron supplementation to identify stellate cell genes tha

283 are indicated to determine the potential of iron supplementation to modulate the clinical severity o

284 months enroled in a randomised, double-blind iron supplementation trial.

285 Iron supplementation was administered in 485 (90.6%) pat

286 Iron supplementation was associated with decreased risk

287 Iron supplementation was associated with greater increas

288 Iron supplementation was associated with improvement in

289 The combination of IPT and iron supplementation was most effective in the treatment

290 Iron supplementation was not associated with offspring B

291 With iron supplementation, weight gains were adversely affect

292 ed from cells grown with different levels of iron supplementation were passed through a 3 kDa cutoff

293 ansporters or iron absorption in response to iron supplementation, whereas down-regulation occurs dur

294 serious adverse events were associated with iron supplementation, whereas, in Nepal, no effects on m

295 Evidence is convincing that maternal iron supplementation will improve birth weight and perha

296 If true, iron supplementation will not be an effective anemia red

297 High-dose iron supplementation with iron dextran after the onset o

298 losses, and the efficacy and safety of oral iron supplementation with versus without prebiotics in t

299 terminants compared to their expression with iron supplementation, yet the quantity of biofilm was no

300 IDA patients can be treated with iron supplementation, yet TT patients have diminished ca